Analysts are weighing in on how Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) , might perform in the near term. Wall Street analysts have a assessment of the stock, with a mean rating of 2.0. The stock is rated as buy by 6 analysts, with 7 outperform and 7 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.
For the current quarter, the 19.00 analysts offering adjusted EPS forecast have a consensus estimate of $1.18 a share, which would compare with $1.44 in the same quarter last year. They have a high estimate of $1.29 and a low estimate of $1.14. Revenue for the period is expected to total nearly $742.51M from $636.21M the year-ago period.
For the full year, 20.00 Wall Street analysts forecast this company would deliver earnings of 5.06 per share, with a high estimate of $5.18 and a low estimate of $4.99. It had reported earnings per share of $4.99 in the corresponding quarter of the previous year. Revenue for the period is expected to total nearly $3.06B versus 2.60B in the preceding year.
The analysts project the company to maintain annual growth of around 20.34% percent over the next five years as compared to an average growth rate of 16.51% percent expected for its competitors in the same industry.
Among the 18 analysts Data provided by Thomson/First Call tracks, the 12-month average price target for ALXN is $187.61 but some analysts are projecting the price to go as high as $221.00. If the optimistic analysts are correct, that represents a 79 percent upside potential from the recent closing price of $123.57. Some sell-side analysts, particularly the bearish ones, have called for $145.00 price targets on shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) .
In the last reported results, the company reported earnings of $1.44 per share, while analysts were calling for share earnings of $1.38. It was an earnings surprise of 4.30%percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH registry; Phase III clinical trials for the treatment of myasthenia gravis, neuromyelitis optica spectrum disorder, and delayed kidney transplant graft function; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. It develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; and ALXN 1007, a novel humanized antibody in Phase II clinical trial for the treatment of anti-phospholipid syndrome and graft versus host disease. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem’s proprietary drug discovery engine; Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for clinical development commercialization of Moderna’s messenger RNA therapeutics to treat rare diseases; and Ensemble Therapeutics Corporation for the identification, development, and commercialization of therapeutic candidates based on specific drug targets. The company was founded in 1992 and is headquartered in New Haven, Connecticut.